Acuamark Diagnostics Announces Addition Of Haywood D. Cochrane To Its Board Of Directors

NEW YORK–(BUSINESS WIRE)– Acuamark Diagnostics, Inc., a biotechnology company that focuses on
developing accurate and cost-effective blood-based screening tests for
the early detection of cancer, today announced the addition of Mr.
Haywood D. Cochrane to its Board of Directors. Mr. Cochrane will
transition from his current position as member of Acuamark Diagnostics’
Advisory Board.

Mr. Cochrane is a seasoned industry executive with over 30 years of
healthcare, laboratory and diagnostics industry experience in executive
and senior management positions. Currently, Mr. Cochrane serves as a
Director of Corium, Inc., and is Vice Chair of the Board of Trustees at
the University Of North Carolina At Chapel Hill.

Mr. Cochrane states: “I am truly delighted to join Bernard, Michael
and Francis and their outstanding Board as we continue to build on this
great technology to commercialize a unique and cost-effective diagnostic
tool in the large and critical area of early-stage cancer detection.”

Previously, Mr. Cochrane served as Chief Executive Officer of CHD
Meridian, Inc., which became the largest provider of integrated, on-site
corporate healthcare management solutions in the United States (now part
of Walgreens). Mr. Cochrane also served as the President and CEO of
Allied Clinical Laboratories (acquired by NHL). Also, he was EVP, CFO
and Treasurer at Laboratory Corporation of America Holdings (LabCorp);
Earlier, he was COO at Biomedical Reference Labs and COO at Roche
Biomedical Labs. Mr. Cochrane has had a variety of public and private
company Board roles, and – amongst others – served as Director at
American Esoteric Labs, Ameripath and Unilab Corporation.

Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. comments: « After
working with Haywood on our Advisory Board, we are very excited to
welcome him to our Board of Directors. He brings a wealth of strategic
and transactional knowledge in the healthcare management and diagnostics
industry.”

Mr. Michael Gargano, Chairman of the Board of Acuamark Diagnostics,
further adds: “We are pleased that Haywood has chosen to join
Acuamark Diagnostics’ Board of Directors. Haywood is a respected pioneer
and leader in the diagnostics industry.”

About Acuamark Diagnostics Inc.

Acuamark Diagnostics is a biotechnology company focused on developing
screening tests for blood-based early detection of cancer. Acuamark
Diagnostics’ technology allows for highly accurate screening of blood to
detect cancer markers at the early cancer stages, before the cancer
becomes untreatable. Backed by a highly experienced team, it is Acuamark
Diagnostics’ mission to contribute to the global battle against cancer
by detecting and attacking cancer through high-precision, early
detection.

For more information, please visit www.acuamarkdx.com,
or contact us at info@acuamarkdx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170108005001/en/